Budoprutug - Climb Bio
Alternative Names: TNT-119Latest Information Update: 20 Jun 2025
At a glance
- Originator Tenet Medicines
- Developer Climb Bio
- Class Anti-inflammatories; Monoclonal antibodies
- Mechanism of Action Antibody-dependent cell cytotoxicity; CD19 antigen inhibitors
-
Orphan Drug Status
Orphan designation is assigned by a regulatory body to encourage companies to develop drugs for rare diseases.
- New Molecular Entity Yes
Highest Development Phases
- Phase I Idiopathic thrombocytopenic purpura; Membranous glomerulonephritis; Systemic lupus erythematosus
- Preclinical Autoimmune disorders